US Patent

US9867810 — Ophthalmic pharmaceutical compositions and uses relating thereto

Method of Use · Assigned to Orasis Pharmaceuticals Ltd · Expires 2037-08-18 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects ophthalmic pharmaceutical compositions containing pilocarpine or a pharmaceutically acceptable salt for correcting presbyopia and other ocular conditions.

USPTO Abstract

The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Drugs covered by this patent

pilocarpine-hydrochloride (PILOCARPINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3741`	—	pilocarpine-hydrochloride

Patent Metadata

Patent number: US9867810
Jurisdiction: US
Classification: Method of Use
Expires: 2037-08-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Orasis Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.